$IRIX News

Iridex Corp (NASDAQ:IRIX) Q1 Loss Narrower Than Expected, Glaucoma Portfolio Strengthens

IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript

Iridex Q1 2026 Earnings Call: Complete Transcript

Iridex Affirms FY2026 Sales Guidance of $51.000M-$53.000M vs $53.227M Est

Iridex Q1 EPS $(0.03) Beats $(0.07) Estimate, Sales $11.799M Miss $11.910M Estimate

Iridex shares are trading higher after the company announced a new partnership with EyeProGPO to expand member access to retina laser technology.

Iridex shares are trading higher after the company announced a new partnership with EyeProGPO to expand member access to retina laser technology.

Iridex Announces New Partnership With EyeProGPO To Expand Access To Retinal Laser Technology

IRIDEX shares are trading lower after the company reported mixed Q4 financial results and issued FY26 sales guidance below estimates.

IRIDEX Corp (NASDAQ:IRIX) Reports Mixed Q4 Results with Revenue Growth and Narrowed Loss

IRIDEX Corporation (IRIX) Q4 2025 Earnings Call Transcript

Iridex Sees FY2026 Sales $51.000M-$53.000M vs $56.549M Est.

Iridex Q4 EPS $(0.01) Beats $(0.02) Estimate, Sales $14.724M Miss $14.740M Estimate.

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

Iridex Announces Plans to Relocate Headquarters

Iridex Intends To Relocate Its Headquarters From Mountain View To San Jose, California

IRIDEX shares are trading higher after the company reported a year-over-year increase in preliminary Q4 and FY25 revenue results.

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

Iridex Reports Preliminary Q4 2025 Revenue Of $14.6M–$14.8M, Up 15%–17% YoY, And Full-Year Revenue Of $52.5M–$52.7M, Up 8% YoY, While Achieving Positive Cash Flow And Adjusted EBITDA

Zacks Initiates Coverage of Iridex With Neutral Recommendation